Research Abstract
Oral mexiletine provides an adjunctive treatment to manage VTAs and reduces appropriate therapies in ICD patients with moderate efficacy and acceptable safety profiles. These observations await confirmation through randomised clinical trials.
Research Date
Research Department
Research Journal
Minerva Cardiology and Angiology
Research Member
Research Pages
622-630
Research Vol
71(6)
Research Website
https://europepmc.org/article/med/36305779
Research Year
2022
Do you have any questions?